Rohto Pharmaceutical Plans December Restart of U.S. Eye Drop Shipments After FDA Disruption

PUBT · 1d ago
Rohto Pharmaceutical Plans December Restart of U.S. Eye Drop Shipments After FDA Disruption
  • Rohto Pharmaceutical's U.S. eye drop sales fell approximately ¥670 million in the first half following FDA restrictions on its Vietnam plant.
  • Sales are expected to fall ¥1 billion to ¥2 billion below the initial plan for the fiscal year ending March 31, 2027.
  • Japan production for the U.S. market is scheduled to resume in November 2026, with phased shipments starting in December.
  • The Vietnam plant resumed production for non-U.S. markets in July following corrective actions; FDA import restrictions apply only to that facility.
  • No adverse health effects have been reported; the U.S. eye drop business is expected to return to normal next fiscal year.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rohto Pharmaceutical Co. Ltd. published the original content used to generate this news brief on November 17, 2026, and is solely responsible for the information contained therein.